Hormonal
Tirzepatide significantly reduces apnea-hypopnea index (AHI) and resolves obstructive sleep apnea (OSA) in obese patients, with approximately 50% achieving resolution after 52 weeks of treatment.
If you have obesity and OSA, tirzepatide (10-15mg weekly) can significantly reduce your apnea severity and may even resolve OSA in half of users after one year. It is not a quick fix; it takes time to lose weight. For severe cases, it should be used alongside CPAP initially, with the goal of potentially reducing CPAP dependence as weight loss occurs. Long-term use is likely necessary to maintain benefits.
There were robust decrements in AHI with resolution of OSA in approximately 50% of subjects.
Why this rating
Based on the SURMOUNT-OSA trial, a landmark double-blind randomized controlled trial with p < .001.
Source
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Allan I Pack et al. · SLEEP · 2025
DOI 10.1093/sleep/zsaf045
More from this paper
- Tirzepatide should be used in combination with CPAP for patients with severe OSA, as the drug takes 6-12 months to significantly reduce AHI, leaving patients at risk during the interim.Good
- Tirzepatide may allow some patients with moderate OSA (AHI 15-30) who are asymptomatic (except for snoring) to discontinue CPAP, as the benefit of CPAP in this subgroup is unclear.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →